Association between SGLT2i, GLP1-RA or DPP-4i use, and risk of incident COVID-19outcome, i.e. presence of a hospitalization with confirmed COVID-19 as main diagnosisin the National Patient Registry or as confirmed COVID-19 as underlying cause of deathin the Cause of Death Registry. This evidence concerns the gene GCG and COVID-19.